Novo mesto, 01 March (STA) - Pharma company Krka has received a ruling from the Supreme Court which rejected a request for audit by Merck Frosst Canada in a patent violation lawsuit. The Supreme Court upheld an earlier ruling by a higher court, which means that the case in Slovenia is closed, the Novo mesto-based company said Friday.
While Krka declined to comment today, its bourse filings from July last year suggest that the Canadian company asked the higher court to ban manufacturing, sales, marketing, and importing of products containing the pharmaceutical ingredient montelukast. The plaintiff also claimed damages for the alleged patent infringement.
The actions were part of a wider dispute regarding the use of montelukast. A lawsuit is ongoing in Finland, where Krka and its Scandinavian subsidiary Krka Sverige have been ordered by the Finnish Court of Appeals to pay almost EUR 630,000 in damages with interest over infringement of patents protecting two manufacturing processes for the montelukast ingredient in Finland.